The investigation began with an unbiased metabolomic survey of mice with chemically induced colitis. Rather than confirming the team’s expectations, the data pointed somewhere unexpected: levels of pantothenate, the vitamin B5-derived precursor of coenzyme A, were markedly elevated in both the colon and serum of colitic animals. Because pantothenate must be phosphorylated by pantothenate kinases, known as PANK enzymes, before it can enter the coenzyme A biosynthetic pathway, its accumulation signaled that the pathway itself was stalled. Of the three PANK isoforms present in the colon, one stood out. PANK3, the dominant intestinal form, was dramatically reduced at both the messenger RNA and protein levels in colitic mice, and the drop was confirmed by immunohistochemical staining of the colonic epithelium.

The downregulation was not merely a rodent curiosity. Analyzing gene expression datasets from human intestinal biopsies, the researchers found PANK3 significantly decreased in patients with active Crohn’s disease and active ulcerative colitis compared with inactive disease and healthy controls. Tissue staining of patient biopsies from Jiangsu Province Hospital corroborated the finding, showing diminished PANK3 specifically within the intestinal epithelium. When human colon epithelial cell lines were exposed to the inflammatory cytokines TNF-alpha and IFN-gamma, PANK3 levels fell again, replicating in a dish what had been observed in diseased tissue. Taken together, the evidence positioned epithelial PANK3 deficiency as a consistent pathological feature of inflammatory bowel disease across species.

To determine whether the loss of PANK3 actually drives barrier failure rather than simply accompanying it, the team deployed a combination of pharmacological and genetic tools. In cultured epithelial cells subjected to inflammatory challenge, a small-molecule PANK3 agonist called PZ-2891 boosted the expression of intercellular junctional proteins, while Hopantenate, a competitive PANK inhibitor, worsened their decline. In Caco-2 monolayer models, transepithelial electrical resistance and paracellular permeability assays showed that activating PANK3 restored barrier function while blocking it deepened the damage. Directly overexpressing PANK3 in HT29 and NCM460 cells rescued inflammation-induced barrier injury, whereas silencing the gene produced the opposite effect, confirming the relationship in both directions.

In living animals the results were even more striking. Mice engineered to overexpress PANK3 specifically in the intestine via adeno-associated virus were markedly protected against DSS-induced colitis, exhibiting less weight loss, shorter reduction in colon length, preserved crypt architecture, maintained goblet cell populations and reduced inflammatory infiltration. Serum FITC-dextran assays demonstrated tighter barrier integrity, and transmission electron microscopy revealed that shortened microvilli and disrupted apical junction complexes were structurally repaired in the PANK3-overexpressing animals. Conversely, intestinal PANK3 knockdown exacerbated every measure of disease severity and barrier breakdown, establishing PANK3 as a necessary guardian of the epithelial lining during colonic inflammation.

The mechanism connecting a metabolic enzyme to such profound structural changes emerged from transcriptomic profiling. PANK3 overexpression suppressed gene clusters encoding proinflammatory cytokines, extracellular matrix components and drivers of epithelial-to-mesenchymal transition, or EMT, a developmental program in which epithelial cells lose their junctions and polarity and take on migratory, mesenchymal characteristics. In chronic inflammation, pathological persistence of EMT dismantles tight junctions and adherens junctions, degrades the basement membrane and promotes fibrotic remodeling, a signature observed in clinical IBD mucosal samples and correlated with disease severity and therapeutic resistance. PANK3, the study found, acts as a powerful brake on this process, downregulating mesenchymal markers such as vimentin and N-cadherin, suppressing the EMT-driving transcription factors Snail and Twist, and preserving junctional proteins including ZO-1, E-cadherin, occludin and claudins.

Gene set enrichment analysis revealed that the EMT-suppressing effects of PANK3 operated through inhibition of the PI3K/AKT and MAPK signaling pathways, both well-established inducers of the transition. Phosphorylation of PI3K, AKT and ERK fell sharply in PANK3-overexpressing mice and rose in knockdown animals, indicating the enzyme’s influence extended deep into canonical signal transduction. The critical mediator proved to be coenzyme A itself. Quantitative LC-MS/MS measurements showed that PANK3 overexpression significantly increased colonic free CoA abundance while knockdown depleted it, and supplying exogenous CoA to cultured epithelial cells was sufficient to suppress inflammation-induced EMT and downstream signaling. When pantothenate was completely removed from the culture medium, the barrier protection conferred by PANK3 agonism or overexpression was largely abolished, confirming that the enzyme’s benefit depends on the raw material for CoA synthesis.

Having established what PANK3 does, the team turned to why it disappears during colitis. Screening transcription factor prediction databases against the Pank3 promoter uncovered c-Myc, the notorious proto-oncogene, as the prime candidate. c-Myc was significantly upregulated in the colonic lesions of ulcerative colitis patients and in multiple experimental colitis models, and chromatin immunoprecipitation confirmed that c-Myc binds directly to three sites in the Pank3 promoter region. A dual-luciferase reporter assay demonstrated that c-Myc overexpression dramatically represses Pank3 promoter activity, and pharmacological inhibition of c-Myc with the inhibitor 10058-F4 restored PANK3 expression in a dose-dependent manner in cells. In mice, c-Myc inhibition ameliorated DSS-induced colitis, rescued PANK3 levels and improved barrier integrity, establishing a clear c-Myc-PANK3-EMT axis in which inflammation-driven c-Myc overexpression silences PANK3, depletes coenzyme A, permits EMT and dismantles the epithelial barrier.

Perhaps the most clinically tantalizing finding came from a high-throughput virtual screen for PANK3 agonists, which identified folic acid, a widely available and inexpensive B vitamin, as the top candidate. Molecular docking predicted binding to key residues including Lys24, Ser192, Arg207, Val268, Asn299 and Trp341, and a cellular thermal shift assay confirmed that folic acid directly stabilizes the PANK3 protein. Oral folic acid at 30 milligrams per kilogram significantly ameliorated DSS-induced colitis in mice, restoring body weight, colon length, crypt architecture and goblet cell populations while elevating colonic coenzyme A levels. Electron microscopy showed repaired microvilli and restored apical junction complexes, junctional proteins were upregulated, EMT markers and matrix metalloproteinases declined, and PI3K/AKT and MAPK activation was suppressed. Crucially, the protection vanished when PANK3 was knocked down, demonstrating that folic acid’s benefit is PANK3-dependent.

The findings carry substantial implications beyond the immediate identification of a druggable target. A meta-analysis cited in the study indicates that higher folate levels are associated with reduced risk of inflammatory bowel disease, lending clinical plausibility to the mechanistic work, although the therapeutic doses used in mice exceed typical supplementation levels and would likely require colon-targeted formulations such as enteric-coated tablets to maximize local exposure while limiting systemic dose. The authors also suggest that circulating pantothenate and coenzyme A levels, together with intestinal PANK3 expression, could serve as accessible biomarkers for diagnosis and treatment monitoring, pending validation in larger multi-center cohorts. Because reduced PANK3 has previously been identified as a diagnostic marker for early-stage colorectal cancer, and c-Myc is a well-established oncogene, the axis also offers a plausible mechanistic thread connecting chronic colitis to malignant transformation. Open questions remain, including precisely how PANK3-derived coenzyme A suppresses the PI3K/AKT and MAPK pathways, whether coenzyme A acts through post-translational modifications such as protein CoAlation, and whether PANK3 possesses non-catalytic functions. Even so, the study reframes ulcerative colitis in part as a metabolic disease of the epithelial barrier and positions PANK3 agonism, potentially through a humble vitamin, as a promising avenue for restoring the gut’s broken wall.

Subject of Research: Metabolic regulation of intestinal epithelial barrier integrity by the c-Myc-PANK3-coenzyme A axis in ulcerative colitis.

Article Title: c-Myc-PANK3-EMT axis regulates the structure and function of intestinal barrier in ulcerative colitis

Article References: Zhang, S., Chen, Y., Aa, N., Xu, C., Xie, T., Wang, Y., Cheng, T., Wang, M., Yu, H., Ji, X., Zhao, S., Wang, Y., Xiao, J., Xie, Y., Wang, G., & Aa, J. (2026). c-Myc-PANK3-EMT axis regulates the structure and function of intestinal barrier in ulcerative colitis. Journal of Advanced Research, 87, 931-946. https://doi.org/10.1016/j.jare.2025.12.007

Image Credits: AI Generated

DOI: 10.1016/j.jare.2025.12.007

Keywords: ulcerative colitis, PANK3, c-Myc, coenzyme A, epithelial-mesenchymal transition, intestinal barrier, folic acid, pantothenate kinase, inflammatory bowel disease, PI3K/AKT pathway, MAPK pathway, tight junctions

The research, led by Ruizhe Huang, Zhiyi Liu and Yawei Zhao under the correspondence of Siyu Chen at the Department of Medical Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, was built on a strikingly broad computational foundation. The team integrated seven single-cell RNA-sequencing cohorts, two spatial transcriptomic cohorts, bulk RNA sequencing linked to patient survival data, CRISPR-based gene essentiality screens, and three independent immunotherapy cohorts. Rather than relying on any single analytical method, the investigators assembled a machine learning framework in which different algorithms handled different parts of the problem, each feeding its output into the next stage of analysis.

The first step involved unsupervised consensus non-negative matrix factorization, a mathematical technique that decomposes gene expression data into coherent transcriptional programs without any prior labeling. Applied to malignant cells across the cohorts, this approach resolved four distinct malignant meta-programs. One of these, designated MP3, carried a mixed mesenchymal and interferon signaling signature, suggesting tumor cells that had partially undergone epithelial–mesenchymal transition while simultaneously mounting inflammatory responses. Crucially, the researchers found that MP3 carried prognostic information only in the context of the other three programs. When considered in isolation, its signal was misleading; when modeled jointly, patients with higher MP3 activity relative to the other programs fared significantly worse, with a hazard ratio of 1.43 per standard deviation and a p-value of 0.0045.

That context-dependence led the team to construct a composite score, essentially the difference between standardized MP3 activity and the activity of a fourth program, MP4, which resembled healthy alveolar cells and was independently protective. This single composite metric, z(MP3) minus z(MP4), proved prognostic on its own, with a hazard ratio of 1.40 and a p-value of 3.4 multiplied by ten to the negative sixth power. The reciprocal balance between an aggressive, plastic mesenchymal state and a differentiated, alveolar-like state thus encoded clinically meaningful information that neither program revealed alone. It is a technical but important lesson: in tumors defined by cellular plasticity, the relative composition of transcriptional states, not the abundance of any one state, appears to determine patient outcomes.

Having established the malignant programs, the researchers turned to the immune microenvironment and deployed deep generative models to interrogate neutrophils. Using scVI and its supervised extension scANVI, probabilistic models designed to denoise single-cell data and transfer cell type labels across datasets, the team resolved distinct neutrophil states within the tumor microenvironment. What emerged was an OSM-primed neutrophil axis. OSM, or oncostatin M, is an inflammatory cytokine, and neutrophils primed with it appeared to participate in a signaling circuit alongside SPP1-positive macrophages, the very cell population that had dominated prior studies of mesenchymal transition in this cancer. The two cell types formed what the authors describe as a partitioned dual circuit, with neutrophils and macrophages occupying complementary roles in sustaining the mesenchymal niche.

What made this finding particularly compelling was its spatial validation. Single-cell data strips away geography, telling researchers which cells exist but not where they sit within the tumor. To recover that geometry, the team applied cell2location, a probabilistic deep learning method for spatial deconvolution that estimates which cell types and states occupy each spot in a spatial transcriptomics slide. They coupled this with random forest multi-view modeling to map communication fluxes between cell populations. The results showed that OSM signaling flux was directed primarily toward macrophages and fibroblasts rather than toward the malignant cells themselves, which means that any influence of the neutrophil circuit on tumor cells is likely indirect, mediated through the stromal and macrophage compartments. The two-compartment niche, pairing OSM-primed neutrophils with their macrophage and fibroblast partners, was reproducible across both spatial cohorts, strengthening confidence that it reflects genuine tumor architecture rather than computational artifact.

The final and perhaps most ambitious stage of the pipeline used Geneformer, a transformer-based single-cell foundation model pretrained on large corpora of gene expression data, to perform in silico gene deletion perturbations. In effect, the model simulates what happens to a cell’s transcriptional state when a particular gene is removed, allowing researchers to computationally screen candidate dependencies across the three coupled state transitions identified in the study: from alveolar-like to mesenchymal malignant states, and through the associated neutrophil and macrophage circuits. The screen converged on SEC61G, a gene encoding a component of the SEC61 translocon, the protein channel in the endoplasmic reticulum membrane through which secreted and membrane proteins pass as they are synthesized. Because mesenchymal tumor cells and inflammatory immune cells both rely heavily on protein secretion, a translocon dependency is biologically plausible.

The authors are notably careful about how they frame this nomination. SEC61G already had independent published support in lung adenocarcinoma, so the team treats it as a positive control re-derived de novo rather than a wholly new drug target. What they report as genuinely new is that SEC61G’s prognostic signal is independent of 7p11.2 copy number, the chromosomal region in which the gene resides and a region frequently amplified in this cancer. In other words, the poor outcomes associated with high SEC61G expression are not simply a reflection of having more copies of the gene, hinting at regulatory or functional dependencies that copy number analysis alone would miss. The overall survival hazard ratio for SEC61G was 1.64 with a p-value of 1.3 multiplied by ten to the negative sixth, and the gene showed higher expression in immunotherapy non-responders in two of the three checkpoint inhibitor cohorts examined, reaching statistical significance in one.

What elevates this study above a typical bioinformatics exercise is its insistence on orthogonal validation. The four-endpoint validation cascade required convergent evidence from survival analysis, immunotherapy response data, CRISPR essentiality screens, and the perturbation modeling itself before any candidate dependency was accepted. This design directly addresses one of the most persistent criticisms of single-cell oncology research: that computational nominations of drug targets often evaporate under experimental scrutiny. By demanding agreement across data types that share no common analytical machinery, the framework filters out candidates whose signals are artifacts of any single method or dataset. The result is a shorter but far more defensible list of candidate targets than a typical computational screen would produce.

The broader significance lies in the generalizability of the approach. The authors explicitly position their strategy, foundation model perturbation followed by multi-endpoint orthogonal validation, as a reusable template for nominating therapeutic targets in plasticity-driven solid tumors, a category that includes many of the hardest cancers to treat. As foundation models like Geneformer mature and spatial transcriptomic datasets accumulate, pipelines of this kind could compress the path from observational single-cell atlases to testable therapeutic hypotheses. For lung adenocarcinoma patients, the immediate deliverables are a newly mapped neutrophil-associated mesenchymal niche that reframes how the tumor microenvironment sustains aggressive cell states, and a candidate translocon dependency whose vulnerability can now be pursued with experimental tools. The work was funded by the National Natural Science Foundation of China and the Shanghai Committee of Science and Technology, and relied exclusively on publicly available, de-identified human data, meaning that its findings can be independently reanalyzed and challenged by any laboratory with computational resources and internet access.

Subject of Research: Deep learning integration of single-cell and spatial transcriptomics to map a neutrophil-associated mesenchymal niche and identify candidate tumor dependencies in lung adenocarcinoma.

Article Title: Deep learning integration of single-cell and spatial transcriptomics reveals a neutrophil-associated mesenchymal niche and a candidate translocon dependency in lung adenocarcinoma

Article References: Deep learning integration of single-cell and spatial transcriptomics reveals a neutrophil-associated mesenchymal niche and a candidate translocon dependency in lung adenocarcinoma. (n.d.). https://doi.org/10.1007/s00262-026-04560-3

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04560-3

Keywords: lung adenocarcinoma, single-cell RNA sequencing, spatial transcriptomics, tumor-associated neutrophils, epithelial–mesenchymal transition, SEC61G, deep learning, tumor microenvironment, Geneformer, immunotherapy response, OSM signaling, cancer prognosis

Hepatoblastoma, characterized by its origins in the liver, has been a subject of concern for pediatric oncologists due to its aggressive nature and the challenges it poses to existing treatment modalities. The etiology of this cancer remains poorly understood, which further complicates therapeutic approaches. The study highlights that the dysregulation of specific long non-coding RNAs (lncRNAs) can lead to significant changes in cellular behavior, thereby contributing to the invasive and metastatic nature of tumors.

In the investigation, the researchers utilized a combination of cellular and molecular biology techniques to elucidate the interactions between lncRNA938, TAF9, and TTK. These components collectively influence the EMT process—a critical mechanism by which epithelial cells transition to a mesenchymal state, thereby gaining increased motility and invasiveness. The findings reveal that the lncRNA938 plays a pivotal role in regulating the expression of TAF9 and TTK, two proteins that are integral to the EMT process.

As the researchers delved deeper, they discovered that the expression levels of lncRNA938 were significantly elevated in hepatoblastoma tissues compared to normal liver tissues. Functional assays demonstrated that the knockdown of lncRNA938 led to a substantial reduction in the invasive and migratory capabilities of hepatoblastoma cells, indicating its contributory role in promoting tumor aggressiveness. These findings underscore the importance of lncRNA938 as a biomarker that could aid in the identification of high-risk patients.

The study did not merely stop at establishing correlations; it ventured into the functional impact of targeting the lncRNA938/TAF9/TTK axis in therapeutic contexts. Utilizing both in vitro and in vivo models, the researchers explored the consequences of disrupting this axis on tumor growth and metastasis. The in vivo experiments, particularly, demonstrated promising results, revealing that silencing lncRNA938 significantly inhibited tumor growth in xenograft models. This discovery points towards the potential for developing targeted therapies that could mitigate the detrimental effects of hepatoblastoma.

Moreover, TAF9 and TTK, being downstream effectors of lncRNA938, emerged as critical players in the signaling pathways that govern cell proliferation and survival. The interplay among these molecules presents an intricate web of regulatory mechanisms where lncRNA938 emerges as a master regulator, orchestrating the expression of genes pivotal for the EMT process. By directly influencing the stability and activity of TAF9 and TTK, lncRNA938 offers a novel insight into the complexities of cancer biology.

Given the aggressive nature of hepatoblastoma and the limited treatment options available, this research holds substantial significance. The identification of the LncRNA938/TAF9/TTK axis as a potential therapeutic target could inspire new treatment paradigms. Efforts are now warranted to translate these findings into clinical applications, which could revolutionize the way hepatoblastoma is treated and managed. Future studies could explore the therapeutic efficacy of small molecules or RNA-based therapies that specifically target lncRNA938 to enhance patient outcomes.

As the research community continues to unravel the complexities of lncRNAs and their roles in cancer, the insights from this study are timely. The growing recognition of lncRNAs as key regulatory molecules in various cancer types begs further exploration into their roles as mediators of tumorigenesis and metastasis. With the advent of advanced genome-editing techniques and RNA-targeting therapeutics, the potential to modify the expression or function of critical lncRNAs presents an exciting frontier in cancer therapy.

The evidence presented in the study certainly paves the way for innovative therapeutic approaches that harness the power of RNA-based interventions. As scientists endeavor to bridge the gap between laboratory findings and clinical applications, the urgency to translate such research into viable treatment strategies for hepatoblastoma becomes paramount.

Furthermore, as researchers collect more data and gain further insights into the regulatory networks orchestrated by lncRNAs, it is conceivable that they will identify additional pathways and targets that could broaden the scope of treatment options for hepatoblastoma and potentially other malignancies. This research not only highlights the role of the LncRNA938/TAF9/TTK axis but also underscores the importance of embracing a multi-faceted approach in cancer research that encompasses both basic science and clinical applications.

In summary, the study on the LncRNA938/TAF9/TTK axis illuminates a promising avenue for therapeutic intervention in hepatoblastoma, propelling forward our understanding of cancer biology. As we stand at the intersection of innovation and healthcare, the findings underscore the imperative to leverage emerging scientific insights into actionable treatment options that could ultimately enhance survival rates for children afflicted with this formidable disease.

Subject of Research: The role of LncRNA938/TAF9/TTK axis in epithelial-mesenchymal transition and its potential as a therapeutic target in hepatoblastoma.

Article Title: LncRNA938/ TAF9/TTK axis promotes EMT and serves as a therapeutic target in hepatoblastoma.

Article References:

Jin, C., Dong, B., Xie, Y. et al. LncRNA938/ TAF9/TTK axis promotes EMT and serves as a therapeutic target in hepatoblastoma. J Transl Med 23, 946 (2025). https://doi.org/10.1186/s12967-025-06809-4

Image Credits: AI Generated

DOI: 10.1186/s12967-025-06809-4

Keywords: LncRNA938, hepatoblastoma, TAF9, TTK, epithelial-mesenchymal transition, therapeutic target, cancer research.

Pancreatic cancer remains notorious for its high mortality rate, largely due to its propensity for early metastasis and resistance to conventional therapies. While the genetic drivers of pancreatic ductal adenocarcinoma (PDAC) have been extensively studied, the intricate molecular machinery underpinning metastasis remains inadequately understood. EMT, the process by which epithelial tumor cells acquire a mesenchymal phenotype, equips these cells with enhanced motility and invasiveness, facilitating their escape from the primary tumor site. Among EMT regulators, ZEB1 stands out as a critical transcription factor orchestrating this phenotypic transformation.

The study puts forward compelling evidence that STN1 plays a facilitating role in the metastatic cascade by acting as a transcriptional activator of ZEB1. Traditionally recognized for its role in telomere maintenance and genome stability as part of the CST complex, STN1’s involvement in transcriptional regulation represents a paradigm shift. Through a series of meticulously designed molecular and cellular experiments, the authors demonstrate that elevated STN1 levels correlate with increased ZEB1 expression, thus promoting EMT and consequently enhancing metastatic potential.

At the heart of this discovery is the demonstration that STN1 directly influences the transcriptional machinery at the ZEB1 promoter. Chromatin immunoprecipitation assays reveal the enrichment of STN1 at specific loci within the ZEB1 gene regulatory regions, suggesting a direct regulatory role. This challenges the traditional view of STN1 exclusively as a structural telomere-binding protein and hints at broader nuclear functions, including modulation of gene expression patterns critical for cancer progression.

Further validation in pancreatic cancer cell lines elucidates that manipulating STN1 expression markedly alters ZEB1 levels. Knockdown of STN1 results in a concomitant decrease in ZEB1 transcription, reversing EMT-associated phenotypes and dampening cell migratory abilities. Conversely, overexpression of STN1 intensifies EMT marker expression and enhances the invasive behavior of cancer cells. These findings robustly establish a causal link between STN1 activity and metastatic traits driven by EMT.

Importantly, the functional assays extend to in vivo models where STN1 modulation impacts tumor spread. Murine xenograft experiments highlight that STN1 depletion hampers metastatic colonization in distant organs, reaffirming the clinical relevance of this pathway. This underscores the potential for STN1 to serve not only as a biomarker for aggressive pancreatic cancer but also as a target for therapeutic strategies aimed at mitigating metastasis.

Mechanistically, the study posits that STN1 may interact with transcriptional co-factors or chromatin remodelers, thereby facilitating an open chromatin state at the ZEB1 promoter conducive to active transcription. Although the precise molecular partners of STN1 in transcriptional regulation remain to be fully elucidated, the identification of this novel function invites a re-examination of CST complex components beyond their canonical roles.

The implications of this research extend beyond pancreatic cancer, as the CST complex and EMT regulators are conserved across various cancer types. Researchers speculate that STN1-mediated transcriptional activation of EMT drivers might be a broader mechanism contributing to tumor aggressiveness in multiple malignancies, thereby broadening the potential impact of future therapies targeting this pathway.

Moreover, this study shines a light on the complex interplay between genome stability maintenance proteins and transcriptional dynamics in cancer biology. The dual functionality of STN1 in maintaining chromosomal integrity and promoting oncogenic transcription programs exemplifies the multifaceted roles proteins can adopt in cancer cells, adapting to facilitate survival and invasion.

The clinical translation of these findings could revolutionize therapeutic approaches. Targeting STN1 or its interactions with the transcriptional apparatus might inhibit ZEB1 expression and EMT progression, thereby stalling metastatic dissemination. Such targeted interventions could enhance the efficacy of existing treatments and improve the dismal survival rates associated with pancreatic cancer.

The research also prompts a revisitation of past genomic and transcriptomic datasets from pancreatic tumors to assess the prognostic value of STN1 expression. Integrating these data with clinical outcomes could establish STN1 as a predictive marker for metastasis, enabling more precise patient stratification and personalized treatment regimens.

While the study elucidates key aspects of STN1’s role in pancreatic cancer metastasis, several questions remain open. Future research is needed to dissect the full spectrum of molecular interactions involving STN1 in the transcriptional regulation landscape and to explore potential crosstalk with other pathways governing EMT and metastasis.

In conclusion, this landmark study exposes STN1 as a novel pro-metastatic factor in pancreatic cancer by fostering ZEB1 transcription and subsequent EMT. It challenges existing dogma surrounding telomere-associated proteins and presents a promising target for intervening in the metastatic cascade. As the fight against pancreatic cancer continues, unveiling such molecular underpinnings offers hope for developing therapies that can ultimately curb metastasis and improve patient outcomes.

Subject of Research:
The role of STN1 in promoting metastasis through transcriptional activation of the EMT regulator ZEB1 in pancreatic cancer.

Article Title:
STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer.

Article References:
Dong, D., Zhou, Z., Zhu, M. et al. STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer. Nat Commun 16, 7815 (2025). https://doi.org/10.1038/s41467-025-63083-0

Image Credits:
AI Generated